BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chevaliez S, Hézode C, Soulier A, Costes B, Bouvier-Alias M, Rouanet S, Foucher J, Bronowicki JP, Tran A, Rosa I, Mathurin P, Alric L, Leroy V, Couzigou P, Mallat A, Charaf-Eddine M, Babany G, Pawlotsky JM. High-dose pegylated interferon-α and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial). Gastroenterology 2011;141:119-27. [PMID: 21439960 DOI: 10.1053/j.gastro.2011.03.039] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
Number Citing Articles
1 Krastinova E, Bani-sadr F, Fromentin D, Goujard C, Hessamfar M, Yazdanpanah Y, Pol S, Cacoub P, Perronne C, Carrat F. Re-treatment of chronic HCV infection in HIV co-infected patients and predictors of sustained viral response. Journal of Infection 2014;68:462-6. [DOI: 10.1016/j.jinf.2013.12.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
2 Berger CT, Kim AY. IL28B polymorphisms as a pretreatment predictor of response to HCV treatment. Infect Dis Clin North Am 2012;26:863-77. [PMID: 23083820 DOI: 10.1016/j.idc.2012.08.010] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
3 Ferreira Cda S, Abreu RM, da Silva MC, Ferreira AS, Nasser PD, Carrilho FJ, Ono SK. A fast and cost-effective method for identifying a polymorphism of interleukin 28B related to hepatitis C. PLoS One 2013;8:e78142. [PMID: 24167602 DOI: 10.1371/journal.pone.0078142] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
4 Jiménez-Sousa MA, Fernández-Rodríguez A, Guzmán-Fulgencio M, García-Álvarez M, Resino S. Meta-analysis: implications of interleukin-28B polymorphisms in spontaneous and treatment-related clearance for patients with hepatitis C. BMC Med. 2013;11:6. [PMID: 23298311 DOI: 10.1186/1741-7015-11-6] [Cited by in Crossref: 60] [Cited by in F6Publishing: 62] [Article Influence: 6.7] [Reference Citation Analysis]
5 Kishida Y, Imaizumi N, Tanimura H, Haruna Y, Kashiwamura S, Kashiwagi T. Restoration of innate and adaptive immune responses by HCV viral inhibition with an induction approach using natural interferon-beta in chronic hepatitis C. Clin Dev Immunol 2012;2012:582716. [PMID: 22966239 DOI: 10.1155/2012/582716] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
6 Palenzuela Gardón D, Guillen IA, Fernández JR, Camacho H, Estevez ZC, Dueñas S, Alvares-Lajonchere L, Amador Y, Martinez-Donato G, Han J, Zhang Z, Zhang X, Gao Y, Campaña JR, Novoa LI. Assessment of IL-28: rs12979860 and rs8099917 Polymorphisms in a Cohort of Cuban Chronic HCV Genotype 1b Patients. J Biomol Tech 2017;28:80-6. [PMID: 28058039 DOI: 10.7171/jbt.17-2801-001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
7 Torres-Cornejo A, Ruiz-Valderas R, Jimenez-Jimenez L, Abad-Molina C, Gutierrez-Valencia A, Viciana P, Lopez-Cortes LF. Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes. J Viral Hepat 2014;21:178-88. [PMID: 24438679 DOI: 10.1111/jvh.12128] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
8 Jõgeda EL, Avi R, Pauskar M, Kallas E, Karki T, Des Jarlais D, Uusküla A, Toompere K, Lutsar I, Huik K. Association of IFNλ4 rs12979860 polymorphism with the acquisition of HCV and HIV infections among people who inject drugs. J Med Virol 2018;90:1779-83. [PMID: 29992584 DOI: 10.1002/jmv.25258] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
9 Salmon-ceron D, Arvieux C, Bourlière M, Cacoub P, Halfon P, Lacombe K, Pageaux G, Pialoux G, Piroth L, Poizot-martin I, Rosenthal E, Pol S. Use of first-generation HCV protease inhibitors in patients coinfected by HIV and HCV genotype 1. Liver Int 2014;34:869-89. [DOI: 10.1111/liv.12363] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
10 Timucin M, Alagozlu H, Ozdemir S, Ozdemir O. Association Between ABCB1 (MDR1) Gene Polymorphism and Unresponsiveness Combined Therapy in Chronic Hepatitis C virus. Hepat Mon 2013;13:e7522. [PMID: 23805158 DOI: 10.5812/hepatmon.7522] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
11 Fischer J, Böhm S, Scholz M, Müller T, Witt H, George J, Sarrazin C, Susser S, Schott E, Suppiah V, Booth DR, Stewart GJ, van Bömmel F, Brodzinski A, Fülöp B, Migaud P, Berg T. Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology 2012;55:1700-10. [DOI: 10.1002/hep.25582] [Cited by in Crossref: 64] [Cited by in F6Publishing: 65] [Article Influence: 6.4] [Reference Citation Analysis]
12 Affandi JS, Hendry S, Waterer G, Thomson R, Wallace H, Burrows S, Price P. Searching for an immunogenetic factor that will illuminate susceptibility to non-tuberculous mycobacterial disease. Human Immunology 2013;74:1382-5. [DOI: 10.1016/j.humimm.2013.06.019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
13 Conti F, Vukotic R, Lorenzini S, Riili A, Cursaro C, Scuteri A, Loggi E, Galli S, Furlini G, Bernardi M, Andreone P. Increase of ribavirin dose improves sustained virological response in HCV-genotype 1 patients with a partial response to peg-interferon and ribavirin. Annals of Hepatology 2014;13:196-203. [DOI: 10.1016/s1665-2681(19)30882-8] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
14 Zhong YW, Zhang HF, Shi YM, Li YL, Chu F, Xu ZQ, Chen DW, Gan Y, Wang FC, Gu ML, Dong Y, Zhu SS, Shi C, Fan HH, Zhang XC, Zhang M. IL28B SNP rs12979860 is the Critical Predictor for Sustained Viral Response in Chinese Children Aged 1 to 6 Years with Chronic Hepatitis C. Int J Biol Sci 2016;12:1357-62. [PMID: 27877087 DOI: 10.7150/ijbs.16220] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
15 Cotte L, Braun J, Lascoux-combe C, Vincent C, Valantin M, Sogni P, Lacombe K, Neau D, Aumaitre H, Batisse D, de Truchis P, Gervais A, Michelet C, Morlat P, Vittecoq D, Rosa I, Bertucci I, Chevaliez S, Aboulker J, Molina J, Aumaitre H, Batisse D, Bernard L, Cheret A, Cotte L, de Truchis P, Dellamonica P, Dominguez S, Gervais A, Girard P, Lucht F, Metivier S, Michelet C, Molina J, Morlat P, Neau D, Pageaux GP, Pol S, Rosa I, Rosenthal E, Vittecoq D, Valantin M, Zucman D; for the French National Agency for Research on AIDS and Viral Hepatitis (ANRS) HC26 Study Group. Telaprevir for HIV/Hepatitis C Virus-Coinfected Patients Failing Treatment With Pegylated Interferon/Ribavirin (ANRS HC26 TelapreVIH): An Open-Label, Single-Arm, Phase 2 Trial. Clinical Infectious Diseases 2014;59:1768-76. [DOI: 10.1093/cid/ciu659] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 2.6] [Reference Citation Analysis]
16 Novotny LA, Evans JG, Su L, Guo H, Meissner EG. Review of Lambda Interferons in Hepatitis B Virus Infection: Outcomes and Therapeutic Strategies. Viruses 2021;13:1090. [PMID: 34207487 DOI: 10.3390/v13061090] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Lemoine M, Chevaliez S, Bastard JP, Fartoux L, Chazouillères O, Capeau J, Pawlotsky JM, Serfaty L. Association between IL28B polymorphism, TNF α and biomarkers of insulin resistance in chronic hepatitis C-related insulin resistance. J Viral Hepat 2015;22:890-6. [DOI: 10.1111/jvh.12408] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
18 Guedj H, Guedj J, Negro F, Lagging M, Westin J, Bochud PY, Bibert S, Neumann AU; DITTO-HCV study group. The impact of fibrosis and steatosis on early viral kinetics in HCV genotype 1-infected patients treated with Peg-IFN-alfa-2a and ribavirin. J Viral Hepat 2012;19:488-96. [PMID: 22676361 DOI: 10.1111/j.1365-2893.2011.01569.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
19 Fülöp B, Biermer M, Cornberg M, Wedemeyer H, Port K, Heyne R, Zeuzem S, Peiffer KH, Welzel T, Herber A, Buggisch P, Moser C, Stoll S, Alshuth U, Berg T. Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders. Liver Int 2015;35:2275-84. [PMID: 25801095 DOI: 10.1111/liv.12832] [Reference Citation Analysis]
20 Oze T, Hiramatsu N, Mita E, Akuta N, Sakamoto N, Nagano H, Itoh Y, Kaneko S, Izumi N, Nomura H. A multicenter survey of re-treatment with pegylated interferon plus ribavirin combination therapy for patients with chronic hepatitis C in Japan. Hepatol Res. 2013;43:35-43. [PMID: 23332086 DOI: 10.1111/j.1872-034X.2012.01056.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
21 Laird ME, Mohsen A, Duffy D, Mamdouh R, LeFouler L, Casrouge A, El-Daly M, Rafik M, Abdel-Hamid M, Soulier A. Apolipoprotein H expression is associated with IL28B genotype and viral clearance in hepatitis C virus infection. J Hepatol. 2014;61:770-776. [PMID: 24905490 DOI: 10.1016/j.jhep.2014.05.040] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
22 Pol S, Aerssens J, Zeuzem S, Andreone P, Lawitz EJ, Roberts S, Younossi Z, Foster GR, Focaccia R, Horban A. Limited impact of IL28B genotype on response rates in telaprevir-treated patients with prior treatment failure. J Hepatol. 2013;58:883-889. [PMID: 23321318 DOI: 10.1016/j.jhep.2012.12.023] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 5.0] [Reference Citation Analysis]